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The misuse of sham controls in examining the eﬃcacy or eﬀectiveness of Complementary and Alternative Medicine has created
numerousproblems.Thetheoreticaljustiﬁcationforincorporatingashamisquestionable.Theshamdoesnotimproveourcontrol
of bias and leads to relativistic data that, in most instances, has no appropriate interpretation with regards to treatment eﬃcacy.
Even the concept of a sham or placebo control in an eﬃcacy trial is inherently paradoxical. Therefore, it is prudent to re-examine
how we view sham controls in the context of medical research. Extreme caution should be used in giving weight to any sham-
controlled study claiming to establish eﬃcacy or safety.
1.Background
The gold standard of clinical trials is the Randomized
Controlled Trial (RCT) [1], with the placebo control as one
of the primary tools to achieve meaningful outcomes. In
exploring the eﬃcacy or eﬀectiveness (hereafter collectively
referred to as “eﬃcacy”) of Complementary and Alternative
Medicine (CAM) therapies, it has been assumed that similar
standards should be applied. This article challenges the
conventional assumption that placebo or sham controls can
and should be used to establish the eﬃcacy of CAM or other
therapies. Speciﬁcally, it addresses the misuse and abuse of
these study designs throughout the medical literature. Given
the inherent paradox of even the concept of a placebo or
sham control, this article argues that such controls should
rarely, if ever, be used in clinical trials designed to establish
whether a given treatment is eﬃcacious. The purpose of the
Sham control is given in the following.
1.1. A Question of Quality. Research into medical procedures
can be divided into four broad questions: (i) Relative safety:
how likely is the procedure to cause more harm than the
disease it is designed to treat? (ii) Eﬃcacy: does a given
medical procedure create a beneﬁcial change? (iii) Mecha-
nisms: how does a given medical procedure produce this
change? and (iv) Economics: how does it compare to other
available treatments with respect to risks, beneﬁts, safety
and eﬀectiveness? Establishing the relative safety of an
intervention is of paramount importance. However, there
is a range of considerations when determining the safety
for a particular intervention, which is beyond the scope
of the current article. Nonetheless, for research on human
subjects, safety should be established prior to evaluating
other outcomes. Thereafter, research can begin to focus on
eﬃcacy.If aninterventionisnot found tobeeﬃcacious, then
committing resources to examine the mechanisms of action
or the economics is not warranted. Historically, sham and
placebo controls (hereafter collectively referred to as “sham”
controls) have been identiﬁed as a useful methodological
considerations to examine the eﬃcacy of a given interven-
tion. Over the past 50 years sham controls have been used in
pharmacological and non-pharmacological study designs to
establish the eﬃcacy ofan activeintervention. However,with
very few exceptions, sham-controlled trials have numerous
limitations, are poorly executed and improperly interpreted.
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scientiﬁcally inappropriate study designs when examining
questions of intervention efﬁcacy.
1.2. Sham Controls and Eﬃcacy. Eﬃcacy is deﬁned as the
extent to which a speciﬁc intervention, procedure, regimen
or service produces a beneﬁcial result under ideal conditions
[2]. Where one is attempting to establish the eﬃcacy of
a given procedure, the study design must be crafted in
a way that has the potential to provide an unequivocal
answer. A sham control has been broadly deﬁned as “a
treatment or procedure that is performed as a control and
that is similar to, but omits a key therapeutic element of the
treatmentorprocedureunderinvestigation” [3].Commonly,
sham controls are implemented because they are believed
to reduce bias by controlling for the ancillary eﬀects of
a procedure [4]. In many instances, particularly in CAM
research, shams are designed to control for psychological
eﬀects in an attempt to examine what is believed to be the
active part of an intervention [5, 6]. For example, in a study
looking at the eﬃcacy of acupuncture for the treatment of
low back pain, a treatment group received acupuncture at
acupuncture points that were hypothesized to actively treat
the pain. A second group received sham acupuncture. In this
group, participants received actual acupuncture; however,
the needles were inserted into acupuncture points that were
not believed to actively treat the pain. By comparing these
twogroups,researcherswereabletocontrolforpsychological
components of the treatment, such as expectation of a
beneﬁt. It is noteworthy that this particular model is often
based on unproven assumptions that placing needles in
alternate or “sham” points will not in any way aﬀect the
speciﬁc outcome measure (in this case, low back pain).
2.Does a ShamActuallyControlforBias?
The use ofa sham requires severalassumptions. Importantly,
it presumes that the psychological aspects of a given proce-
dure are ancillary to the procedure. However, this has never
beenestablished.To thecontrary, thereismounting evidence
that psychological eﬀects may in fact be relatively unique
and, therefore, non-ancillary aspects of any given interven-
tion. In an interesting study, Kaptchuk and colleagues at
Harvard University [7] compared two diﬀerent forms of
placebo: sham acupuncture and a sham pharmaceutical pill
(aka placebo pill) and they assessed the eﬀects on headaches.
As both a placebo pill and a sham technique are presumed
to be inert, it was surprising that sham acupuncture was
signiﬁcantly more eﬀective at relieving headaches than the
sham pill. This and other studies demonstrating the wide
range of eﬀects that various placebos and shams can have on
a given outcome measure strongly question the underlying
assumption that psychological eﬀects are distinct entities
from anygivenintervention.Ifapsychologicalcomponentof
an intervention improves outcomes, but is relatively speciﬁc
to that intervention, then it may not be appropriate to try to
removethat component in an eﬃcacytrial [8].Assuch, itisa
mistake to assume that psychological factors are ancillary to
agivenproceduredefacto[9].Consequently,anyassumption
a researcher makes that psychological factors are ancillary
introduces bias, because this assumption has never been
found to be accurate. While using a sham to control for
psychological eﬀects may remove some of the patient bias,
it introduces an experimenter bias. Ultimately, we merely
substitute one bias for another and the aggregation of bias
is not improved.
3.Does a Sham Improve the Quality of Results
inEfﬁcacyStudies?
The next question is whether controlling for subject expec-
tation improves the quality and value of the ﬁndings
from eﬃcacy studies. In many sham studies, the treatment
procedure is altered to prevent the subject from being able
to diﬀerentiate an active treatment from a sham treatment.
W h i l et h i si m p r o v e st h eb l i n d i n go fp a t i e n t s ,i td o e ss o
at the expense of obtaining an accurate assessment of
the interventions potential eﬃcacy. The contrived blinding
technique oftenalters the actual conditionsinwhich patients
are being treated in the real world. As a result, one is
studying a procedure that is not in clinical use. The results
of the study, therefore, are not necessarily applicable to the
procedure the researchers originally intended to study. For
example, in acupuncture research, one of the most often-
used sham needlesrequires theuse of a relatively large plastic
device, which alters the actual feel of the needle to both
the practitioner and the patient. While this has been shown
to eﬀectively blind subjects, it also alters the practitioner’s
dexterity in needle manipulation [10]. Therefore, because
the use of sham devices oftentimes reﬂects neither ideal
conditions nor standard clinical conditions, we do not get
quality data on whether the procedure is eﬃcacious or
eﬀective. In some cases, there may be procedures and shams
that can exactly duplicate real world scenarios and avoid the
aforementioned pitfalls. For example, it could be that the
ritualoftakingacertainkindofshampillmaybenodiﬀerent
than taking an active pill. However, even in such a case, the
introduction of a sham to an eﬃcacy trial creates fatal ﬂaws.
4.FatalFlaws:Smoke andMirrors
Imagine the following scenario: Researchers attempt to
examine the eﬃcacy of acupuncture for improving preg-
nancy outcomes. To do so, a simple randomized, sham-
controlled trial is set up comparing true acupuncture to
sham acupuncture. In this case, the only diﬀerence between
the active group and the sham group is the selection of
acupuncture points. As such, subject bias is not an issue.
Furthermore, the active treatment has not been altered by
t h eu s eo fas h a mn e e d l e ;t h e r e f o r et h ea c t i v ei n t e r v e n t i o ni s
representative of actual clinical care. However, we now have
a more severe issue. In this scenario, the results of the study
showed thattheacupuncturegroupachieveda60%livebirth
rate and the sham group achieved a 50% live birth rate. The
diﬀerence was not statistically signiﬁcant. What conclusions
can be drawn? The only conclusion one can properly make
from this study is there is no signiﬁcant diﬀerence betweenEvidence-Based Complementary and Alternative Medicine 3
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Figure 1: Possible eﬀects of a sham control.
those two acupuncture point combinations. One cannot
conclude anything at all about the eﬃcacy of acupuncture,
which was the stated objective of the study. The fatal ﬂaw
of this, and any other sham-controlled study that does not
include a non-treatment control group or properly validated
sham [6], is that the study is completely relativistic. There is
no way of knowing if the ﬁndings are a false positive, false
no-eﬀect or false negative.
Consider the following illustration (Figure 1):
There are four possible scenarios for any simple sham-
controlled study. The ﬁrst possibility is that the sham truly
has no eﬀect on the outcome measure. In such a case,
the sham is inert and, as such, is equivalent to having no
placebo at all. The second possibility is that the sham has
an e g a t i v ee ﬀect on the outcome measure. This results in a
falsepositive,wheretheactualtreatment looksmoreeﬀective
than it really is. The third scenario is that the sham has a
slightly positive eﬀect on the outcome measure. In such a
case, it appears that the actual treatment has done nothing.
Thefourthscenarioisthatthesham has asubstantialpositive
eﬀect on the outcome measure. In such a case, the actual
treatment artiﬁcially appears to have a negative eﬀect on the
outcome. One of the above scenarios is always present in
any sham-controlled study. Unless there exists either a non-
treatment control group as an additional arm, or a sham that
has been validated against the investigated outcome measure
(which is exceedingly rare), it is impossible to know which
scenario is occurring. As a result, the ﬁndings of most sham-
controlled studies fail to provide data on the true eﬀects of
a given treatment. Study analyses and conclusions, however,
rarely acknowledge this and frequently make unwarranted
conclusions about the eﬃcacy of a procedure [11], resulting
in the discarding of valid procedures and the acceptance of
procedures that may not be eﬃcacious.
One unfortunate area where this confusion is perpet-
uated is in the establishment of safety data. For example,
the New England Journal of Medicine (NEJM) published
a study on the quadrivalent HPV vaccine (Gardasil) [12],
examining its eﬃcacy and safety. The researchers compared
the vaccine to a sham vaccine (placebo). The sham, however,
contained aluminum compounds that are known to cause
adverse reactions [13, 14]. The researchers concludedthat:
There were relatively few side eﬀects of vacci-
nation [emphasis added]. The proportion of
subjects who reported one or more injection-
site adverse events was higher in the vaccine
group than in the placebo group (84.4% versus
77.9%)... O n es u b j e c ti nt h ep l a c e b og r o u p
discontinued participation owing to a serious
injection-related adverse event (hypersensitiv-
ity). The proportions of women reporting seri-
ous adverse events were similar in the two treat-
ment groups... [N]o safety concerns among
non-pregnant women were identiﬁed [in this
trial] [12].
Clearly, concluding that a vaccine is safe based on such a
trial design is grossly misleading and irresponsible. Because
the vaccine appears to have the same high level of adverse
events as the placebo does not mean that the vaccine is thus
safe.
5.A PlaceboParadox:The Inherent
Inconsistencies ofSham-Controlled
EfﬁcacyTrials
As the Gardasil trial demonstrates, shams are not necessarily
inert. However, a placebo or sham is supposed to be “a
substance or procedure...that is objectively without speciﬁc
activity for the condition being treated” [15]. Objectivity
means that it must be validated through a controlled trial
demonstrating no eﬀect on the outcome measure. In the
NEJM study, there was no mention that the sham had been
objectively studied to have no eﬀect on safety or on cervical
cancer. This leads us to a paradox: one cannot use a sham
that shows an eﬀect on the outcome measure because it is
not“withoutspeciﬁc activityfortheconditionbeingtreated”.
In other words, it’s not inert. For example, if a proposed
sham for a study on pregnancy rates increases pregnancy
rates, it is an active treatment and therefore one cannot use
it as a “sham”. On the other hand, if a sham objectively does
not show any eﬀect on the outcome measure then, while it
is inert, there obviously is no “placebo eﬀect”. The whole
reason for a placebo control study design is to control for a
hypothesizedplaceboeﬀect.Inotherwords,ifthecontrolhas
no eﬀect on the outcome measure, then there is no placebo
eﬀect either. If the control has no placebo eﬀect, it is no
diﬀerent than using a non-treatment control (Figure 2). In
such a case, it would waste resources that could potentially
be used to increase the power of the study [10].
6.Conclusion
In conclusion, study design needs to be re-examined in light
of modern medical knowledge. Sham studies cannot be used
to establish eﬃcacy except under one of two conditions.4 Evidence-Based Complementary and Alternative Medicine
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Figure 2: Placebo eﬀect paradox in an eﬃcacy trial.
The ﬁrst condition is that a third arm is used in the study
that contains a non-treatment control or a validated sham.
The second is that the sham must be validated against
the outcome measure being examined. However, of note, a
validated sham needs to be inert, without an eﬀect on the
outcome measure and therefore without a placebo eﬀect.
Thus, it should not be used in eﬃcacy trials as it wastes
resources that could be used to improve the power of the
trial. The idea that controlling for the placebo eﬀect is
necessary for a quality eﬃcacy study is, in part, based on
outdated concepts that psychological factors are generic and
non-unique. This has never been proven and, in fact, more
recent studies are suggesting the contrary. Therefore, it is of
no beneﬁt in eﬃcacy trials to try to control for any eﬀects
that can potentially only be achieved through the particular
procedure being examined.
In reality, shams- and placebo-controlled trials are
merely comparative trials. Once eﬃcacy is established for a
givenmodality,controllingforvariousaspectsofaprocedure
can give us useful information regarding the mechanisms by
whichsuchprocedureproducesitsbeneﬁcialresults.Thiscan
be important in further reﬁning and improving treatments.
However, it is irrational to conducta study to examine which
aspects of a procedure are responsible for its beneﬁt, if such
beneﬁt has not ﬁrst been established. It is therefore prudent
to re-examine how we view sham controls in the context of
medical research. While they can be useful in the contextof a
comparative trial, extreme caution should be used in giving
weight to any sham controlled study claiming to establish
eﬃcacy or safety.
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